These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1089 related articles for article (PubMed ID: 32376954)

  • 41. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration.
    Franzmeier N; Suárez-Calvet M; Frontzkowski L; Moore A; Hohman TJ; Morenas-Rodriguez E; Nuscher B; Shaw L; Trojanowski JQ; Dichgans M; Kleinberger G; Haass C; Ewers M;
    Mol Neurodegener; 2020 Oct; 15(1):57. PubMed ID: 33032659
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment.
    Blautzik J; Kotz S; Brendel M; Sauerbeck J; Vettermann F; Winter Y; Bartenstein P; Ishii K; Rominger A;
    J Alzheimers Dis; 2018; 65(3):781-791. PubMed ID: 28697560
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology.
    Miners JS; Kehoe PG; Love S; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2019 Sep; 11(1):81. PubMed ID: 31521199
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.
    Osorio RS; Ayappa I; Mantua J; Gumb T; Varga A; Mooney AM; Burschtin OE; Taxin Z; During E; Spector N; Biagioni M; Pirraglia E; Lau H; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Rapoport DM; de Leon MJ
    Neurobiol Aging; 2014 Jun; 35(6):1318-24. PubMed ID: 24439479
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
    Chételat G; Fouquet M
    Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reconstruction of the human blood-brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes.
    Blanchard JW; Bula M; Davila-Velderrain J; Akay LA; Zhu L; Frank A; Victor MB; Bonner JM; Mathys H; Lin YT; Ko T; Bennett DA; Cam HP; Kellis M; Tsai LH
    Nat Med; 2020 Jun; 26(6):952-963. PubMed ID: 32514169
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ApoE4-mediated blood-brain barrier damage in Alzheimer's disease: Progress and prospects.
    Zhou X; Shi Q; Zhang X; Gu L; Li J; Quan S; Zhao X; Li Q
    Brain Res Bull; 2023 Jul; 199():110670. PubMed ID: 37224887
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of
    La Joie R; Visani AV; Lesman-Segev OH; Baker SL; Edwards L; Iaccarino L; Soleimani-Meigooni DN; Mellinger T; Janabi M; Miller ZA; Perry DC; Pham J; Strom A; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Neurology; 2021 Feb; 96(5):e650-e661. PubMed ID: 33262228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound.
    Meng Y; Goubran M; Rabin JS; McSweeney M; Ottoy J; Pople CB; Huang Y; Storace A; Ozzoude M; Bethune A; Lam B; Swardfager W; Heyn C; Abrahao A; Davidson B; Hamani C; Aubert I; Zetterberg H; Ashton NJ; Karikari TK; Blennow K; Black SE; Hynynen K; Lipsman N
    Brain; 2023 Mar; 146(3):865-872. PubMed ID: 36694943
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MicroRNA-195 rescues ApoE4-induced cognitive deficits and lysosomal defects in Alzheimer's disease pathogenesis.
    Cao J; Huang M; Guo L; Zhu L; Hou J; Zhang L; Pero A; Ng S; El Gaamouch F; Elder G; Sano M; Goate A; Tcw J; Haroutunian V; Zhang B; Cai D
    Mol Psychiatry; 2021 Sep; 26(9):4687-4701. PubMed ID: 32632205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.
    Fortea J; Pegueroles J; Alcolea D; Belbin O; Dols-Icardo O; Vaqué-Alcázar L; Videla L; Gispert JD; Suárez-Calvet M; Johnson SC; Sperling R; Bejanin A; Lleó A; Montal V
    Nat Med; 2024 May; 30(5):1284-1291. PubMed ID: 38710950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina.
    Shi H; Koronyo Y; Rentsendorj A; Regis GC; Sheyn J; Fuchs DT; Kramerov AA; Ljubimov AV; Dumitrascu OM; Rodriguez AR; Barron E; Hinton DR; Black KL; Miller CA; Mirzaei N; Koronyo-Hamaoui M
    Acta Neuropathol; 2020 May; 139(5):813-836. PubMed ID: 32043162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease.
    Zlokovic BV
    JAMA Neurol; 2013 Apr; 70(4):440-4. PubMed ID: 23400708
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.
    Monsell SE; Kukull WA; Roher AE; Maarouf CL; Serrano G; Beach TG; Caselli RJ; Montine TJ; Reiman EM
    JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.